These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20462263)

  • 1. Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
    Wang S; Midgley CA; Scaërou F; Grabarek JB; Griffiths G; Jackson W; Kontopidis G; McClue SJ; McInnes C; Meades C; Mezna M; Plater A; Stuart I; Thomas MP; Wood G; Clarke RG; Blake DG; Zheleva DI; Lane DP; Jackson RC; Glover DM; Fischer PM
    J Med Chem; 2010 Jun; 53(11):4367-78. PubMed ID: 20462263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
    Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
    Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
    Jani JP; Arcari J; Bernardo V; Bhattacharya SK; Briere D; Cohen BD; Coleman K; Christensen JG; Emerson EO; Jakowski A; Hook K; Los G; Moyer JD; Pruimboom-Brees I; Pustilnik L; Rossi AM; Steyn SJ; Su C; Tsaparikos K; Wishka D; Yoon K; Jakubczak JL
    Mol Cancer Ther; 2010 Apr; 9(4):883-94. PubMed ID: 20354118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective aminothiazole aurora kinase inhibitors.
    Andersen CB; Wan Y; Chang JW; Riggs B; Lee C; Liu Y; Sessa F; Villa F; Kwiatkowski N; Suzuki M; Nallan L; Heald R; Musacchio A; Gray NS
    ACS Chem Biol; 2008 Mar; 3(3):180-92. PubMed ID: 18307303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.
    Ma YZ; Tang ZB; Sang CY; Qi ZY; Hui L; Chen SW
    Bioorg Med Chem Lett; 2019 Mar; 29(5):694-699. PubMed ID: 30728112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.
    Kamei H; Jackson RC; Zheleva D; Davidson FA
    J Pharmacokinet Pharmacodyn; 2010 Aug; 37(4):407-34. PubMed ID: 20694801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Cyano-6-(5-methyl-3-pyrazoloamino)pyridines: selective Aurora A kinase inhibitors.
    Ando R; Ikegami H; Sakiyama M; Ooike S; Hayashi M; Fujino Y; Abe D; Nakamura H; Mishina T; Kato H; Iwase Y; Tomozane H; Morioka M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4709-11. PubMed ID: 20573509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
    Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
    Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
    Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
    Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.
    Ratushny V; Pathak HB; Beeharry N; Tikhmyanova N; Xiao F; Li T; Litwin S; Connolly DC; Yen TJ; Weiner LM; Godwin AK; Golemis EA
    Oncogene; 2012 Mar; 31(10):1217-27. PubMed ID: 21785464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
    Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
    ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.
    Xie H; Lee MH; Zhu F; Reddy K; Peng C; Li Y; Lim DY; Kim DJ; Li X; Kang S; Li H; Ma W; Lubet RA; Ding J; Bode AM; Dong Z
    Cancer Res; 2013 Jan; 73(2):716-24. PubMed ID: 23117881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.
    Lawrence HR; Martin MP; Luo Y; Pireddu R; Yang H; Gevariya H; Ozcan S; Zhu JY; Kendig R; Rodriguez M; Elias R; Cheng JQ; Sebti SM; Schonbrunn E; Lawrence NJ
    J Med Chem; 2012 Sep; 55(17):7392-7416. PubMed ID: 22803810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
    Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
    Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.